The world’s first plant-based COVID-19 vaccine candidate has proven to be more than 75% effective against preventing the Delta variant of the virus, a Canadian drugmaker said Tuesday.
Medicago’s vaccine was 75.3% effective against the variant when boosted with GlaxoSmithKline’s booster, according to a late-stage study from both companies.
“These are encouraging results, as the data was obtained in an environment where no ancestral virus is circulating. The global COVID-19 pandemic continues to show new facets with the current dominance of the Delta variant, the emerging Omicron and other variants likely to follow,” said Thomas Breuer, GSK’s Chief Global Health Officer, in a statement.
The vaccine uses a technology known as virus-like particles produced in plant cells, which mimic the structure of the coronavirus but contain no genetic material from it.
The overall efficacy of the vaccine was 71% against all variants of the coronavirus except Omicron, which was not yet known to be circulating when the study was underway.
The trial involved more than 24,000 participants ages 18 and older in Canada, the United States, the United Kingdom, Mexico, Argentina and Brazil.
Medicago said it plans to seek regulatory approval for Health Canada’s plant-based COVID-19 vaccine.
With Post wires